Other research shows treatment leads to high patient satisfaction
Swallowing pills containing a concentrate of fecal bacteria successfully stops recurrent bouts of debilitating Clostridium difficile (C. diff) infection by rebalancing the bacteria in the gut, suggests a study being presented at the IDWeek 2013™ meeting today.
Infection from C. diff bacteria is such a concern that the Centers for Disease Control and Prevention (CDC) named it one of the three most urgent threats in its recent landmark report on antibiotic resistance. C. diff sickens half a million Americans and kills 14,000 every year. C. diff infection can occur after people take antibiotics, wiping out the good bacteria in the gastrointestinal (GI) system, allowing C. diff to flourish and leading to severe diarrhea. In some patients, infection continues to recur despite standard treatment with antibiotics. For patients trapped in that cycle, doctors have transplanted feces from healthy donors into their GI system to rebalance the bacteria and stop infections from recurring.
Fecal transplantation typically is delivered by enema, colonoscopy (placing a tube in the colon) or nose tube and is effective in nine out of 10 patients, according to published reports. The IDWeek research suggests the less-invasive pills are a viable and effective delivery method.
“Recurrent C. diff infection is such a miserable experience and patients are so distraught that many ask for fecal transplantation because they’ve heard of its success,” said Thomas Louie, MD, professor of medicine at the University of Calgary, Alberta, and lead author of the pill study. “Many people might find the idea of fecal transplantation off-putting, but those with recurrent infection are thankful to have a treatment that works.”
Indeed, additional research being presented at the meeting showed patients who received fecal transplantation through a tube in the nose were highly satisfied with the treatment, and said they would likely recommend it to a friend.
Fecal Transplantation by Pill
University of Calgary researchers reported a 100 percent success rate – none of the 27 patients who took the tablet-sized pills had a recurrence of C. diff, even though all of them previously had had at least four bouts of the infection. Patients ingested between 24 and 34 capsules containing fecal bacteria, often donated by family members.
To make the pills, researchers processed the feces until it contained only bacteria, and then encapsulated the bacterial concentrate inside three layers of gelatin capsule. This ensured the pills wouldn’t leak or disintegrate until they were past the stomach and into the small intestine – a potential advantage over other methods because it covers more of the GI tract, does not involve invasive and more costly procedures, and is more comfortable for patients, Dr. Louie said.
Dr. Louie said he first made pills for fecal transplantation when one patient failed to respond to the enema method on two occasions and also could not tolerate a nasal tube for medical reasons. The pills are made individually.
“The pills are a one-shot deal and seem to work. They are easier for patients and are well-tolerated,” said Dr. Louie. “It’s an exciting development in the field and could possibly even be used to maintain the balance of bacteria in the GI system in patients at risk for C. diff.””
Patient Satisfaction of Fecal Transplantation
In the study of fecal transplantation tolerance, researchers surveyed 28 patients three months after they had undergone the treatment through a tube fed through the nose and GI system to the small intestine. On a scale of one to 10, average patient scores were: 9.6 for overall satisfaction; 9.9 for ease; and 9.9 for likelihood of recommending the procedure to a family member or friend.
“Patients with C. diff often have 20 or more stools a day, which seriously affects quality of life and so they are very open to this treatment,” said Ravi Kamepalli, MD, an infectious diseases physician at the Regional Infectious Disease-Infusion Center, Lima, Ohio, and lead author of the study. “Human beings are 90 percent bacteria and once that balance is altered with antibiotics, opportunistic infections can cause serious problems. All we are doing with this treatment is resetting the balance.”
The Latest on: Clostridium difficile
- Global HAIs Control Market Growth Probability, Key Vendors and Future Scenario Up to 2024 on April 18, 2019 at 9:03 pm
For instance, Clostridium difficult bacterium caused serious infections in the U.S. hospitals and nursing homes. Researchers from the University of Michigan started the work with $7.5 Million to ... […]
- DEINOVE invited to present at the 29th congress of the European Society of Clinical Microbiology and Infectious Diseases on April 11, 2019 at 10:30 pm
It is developed as a highly active 1 st line treatment targeting Clostridium difficile. It has demonstrated significant efficacy and superiority to reference treatments (fidaxomicin in particular ... […]
- Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile on April 11, 2019 at 7:08 am
Company Provides Update on Status of IMM-529 Clinical Trial and New Strategic Focus Key Points C. difficile remains a major medical problem, causing an estimated annual economic burden of more than ... […]
- mRCC: Identifying and Managing AEs in TKIs and IO Therapy on April 9, 2019 at 1:08 pm
But I had a patient who was 5 hours away, and he was having 30 bowel movements a day in the ER [emergency department], and they said, “Oh, we’re working up for C diff [Clostridium difficile].” And so ... […]
- How to Recover Gut Health After Clostridium difficile Infection on March 20, 2019 at 6:44 pm
Clostridium difficile (C. difficile) is a common bacterial gastrointestinal infection, causing almost half a million cases of illness in the United States each year. Recovery from a C. difficile ... […]
- What is Clostridium difficile? on March 18, 2019 at 8:51 pm
What are the characteristics of C. difficile infection? Clostridium difficile is a Gram-positive bacterium that induces inflammation in the intestine via two toxins, namely TcdA and TcdB. A variety of ... […]
- Analysis on Global Clostridium difficile Partnering Deals & Agreements, 2014 to 2019 - ResearchAndMarkets.com on March 13, 2019 at 8:12 am
DUBLIN--(BUSINESS WIRE)--The "Global Clostridium difficile Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering. This report provides understanding and access to ... […]
- Analysis on Global Clostridium difficile Partnering Deals & Agreements, 2014 to 2019 - ResearchAndMarkets.com on March 13, 2019 at 5:42 am
The "Global Clostridium difficile Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering. This report provides understanding and access to partnering deals and agreements ... […]
- Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner on January 30, 2019 at 11:04 pm
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, is ... […]
- Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Insight, 2019 - ResearchAndMarkets.com on January 22, 2019 at 4:45 am
DUBLIN--(BUSINESS WIRE)--The "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. ... […]
via Google News and Bing News